Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EACarl who wrote (300)	1/11/2008 1:26:08 AM
From: tuck	of 684

>>Time to wake this thread up! ANDS now down to $1.44, last cash reported at $2.15. No debt, tangible BV $2.19.<< Yawn. Well, we know they have no product, so the question is can their cash reserves fund development of molecules to the point that they can be monetized -- at least to phase one. Do they have anything beyond P1? What's their burn rate on their preclinical stuff? I vaguely remember they have an interesting preclinical anti-infective program. What's their development strategy? Some decent deals have been done recently for P1 compounds (Intermune's HCV program, for instance). What's the chart say? Actually I was about to go to sleep. Be careful with the multiple posts. You're an old hand here on SI; you know that similar posts on 3 different threads is officially considered spam? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next